Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, safety, tolerability and efficacy of artemether + lumefantrine dispersible tablet in neonates/infants <5 kg with uncomplicated Plasmodium falciparum malaria
2023-000804-21Phase 2
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of artemether and lumefantrine in malaria, sponsored by Novartis. Primary endpoint: ART Cmax.
02
Drugs
artemetherlumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on 2023-000804-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000804-21.